Inhalation drug products for respiratory delivery have been widely accepted for localized treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). It also provides a promising alternative route for systemic drug administration for small molecules and large molecule biologics. An estimated 300 million people worldwide have asthma, and 65 million have moderate to severe COPD according to a World Health Organization (WHO) estimate. The global inhalation and nasal generic drug market was valued at $17.5 billion in 2021 and is expected to expand at a compound annual growth rate of approximately 9% to 2030.
Aucta is currently expending its inhalation product portfolio to fulfill unmet clinical needs on the international market. Market research indicates a high demand in affordable medication for the treatment of a broad range of respiratory ailments in China, the United States, and other regions.
The roadmap to successful development of inhaled products is challenging and requires expertise and synergy in drug formulation, device characterization, and quality control. Our team’s extensive experience and technical capability in inhalation product development makes us a strong contender in such a niche market. Using our comprehensive in vitro bioequivalence platform, combining state of the art techniques such as Aerodynamic Particle Size Distribution (APSD), Fine Particle Dose (FPD), Delivered-Dose Uniformity (DDU), Delivery Rate (DR), Total Delivered Drug (TDD), and the Population Bioequivalence (PBE) statistical analysis method, Aucta can shorten the product development cycle and accelerate the commercial market access.